Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Capricor Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -5.3100 | -8.000 | 4 | 5 | -6 | -214 | -5 | -5 | -13 | -5 | 3 | 62 |
| 2016 | -8.0900 | -9.850 | 3 | 4 | -12 | -263 | -12 | -4 | -26 | -4 | 4 | 46 |
| 2017 | -10.1400 | -5.400 | 3 | 2 | -18 | -144 | -18 | -2 | -33 | -2 | 4 | 31 |
| 2018 | 1.0000 | -5.750 | 1 | 1 | 2 | -153 | -12 | -1 | -23 | -1 | 4 | 13 |
| 2019 | -5.1700 | -1.965 | 1 | 0.84 | -15 | -52 | -15 | 0.83 | -27 | 0.83 | 4 | 9 |
| 2020 | -1.9900 | -0.880 | 1 | 0.25 | -7 | -23 | -7 | 0.25 | -12 | 0.25 | 3 | 2 |
| 2021 | -0.8700 | -0.800 | 0.31 | 0.22 | -13 | -21 | -13 | 0.22 | -22 | 0.22 | 5 | 2 |
| 2022 | -0.8400 | -1.217 | 0.24 | 1 | -19 | -32 | -20 | -1 | -21 | -1 | 7 | 18 |
| 2023 | -1.1800 | -1.040 | 2 | 21 | -29 | -27 | -29 | -20 | -30 | -20 | 10 | 240 |
| 2024 | -0.8300 | -1.199 | 25 | 20 | -22 | -32 | -23 | -20 | -24 | -20 | 12 | 239 |
| 2025 | - | -1.013 | - | 44 | - | -40 | - | -43 | - | -44 | - | 507 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |